Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-263 in Indolent Systemic Mastocytosis
NCT04910685Phase 3Recruiting
- Sponsor
- Blueprint Medicines
- Start
- Nov 2021
- Primary completion
- Sep 2032
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 25
01
Overview
A Phase 3 trial of elenestinib in indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), sponsored by Blueprint Medicines. Started Nov 2021; status: recruiting.
02
Drugs
elenestinib
03
Conditions
indolent systemic mastocytosis (ISM)smoldering systemic mastocytosis (SSM)
Beyond the preview
Go deeper on NCT04910685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04910685.